STOCKHOLM, Feb. 14, 2019 /PRNewswire/ --
Throughout 2018, we continued to build on our mission to develop
and validate accurate bloodbased diagnostic tests that can make a
real and significant impact on healthcare worldwide and to initiate
the exciting activities to commercialize those efforts.
As we accelerated the preparations for the commercialization of
IMMray™ PanCan-d, our lead diagnostic candidate for the early
detection of pancreatic cancer, Immunovia completed the expansion
of our production and sample testing facilities, IMMray™ Dx
Laboratories, at our headquarters in Lund, Sweden. This new state-of-the-art
facility, working in conjunction with our IMMray™ Dx Laboratories
at our subsidiary in Marlborough,
MA, allows us the capacity and capability to produce slides
to not only meet the current foreseen demands for commercial
testing but at the same time meet the demands of the large
prospective studies to be performed in parallel.
We worked diligently to establish and expand the world's most
comprehensive set of prospective clinical trials within the area of
detection of pancreatic cancer for IMMray™ PanCan –d consisting of
three large studies, PanSYM-1, PanFAM-1 and PanDIA-1.
We also identified two additional strategic focus areas adding
to our pipeline activities in 2018 –non-small cell lung cancer
(NSLC) and Rheumatoid Arthritis (RA). Both indication areas address
very large unmet clinical needs, in focus of the global healthcare
systems, and thereby represent tremendous commercial opportunities
for Immunovia adding to our main focus on earlier detection of
pancreatic cancer.
On the corporate side, we rounded out the first quarter of 2018
with the announcement of an important corporate milestone:
Immunovia's application to move its shares to the Main Market, Mid
Cap segment on Nasdaq Stockholm. Our shares commenced trading on
April 3, 2018. This move not only
reflects that we have matured as a company, but it also strengthens
our brand and furthers awareness of our work as we move closer to
commencing commercial activities.
Mats Grahn, CEO of Immunovia
AB
Key Indicators
Key Indicators (SEK
thousand unless otherwise stated)
|
Oct-Dec
2018
|
Oct-Dec
2017
|
Full year
2018
|
Full year
2017
|
Net Sales
|
91
|
26
|
333
|
149
|
Operating
earnings
|
-25,756
|
-15,362
|
-87,708
|
-45,520
|
Earnings before
tax
|
-25,655
|
-15,318
|
-86,531
|
-45,232
|
Net
earnings
|
-25,655
|
-15,318
|
-86,536
|
-45,232
|
Earnings per share
before and after dilution (SEK/share)
|
-1.31
|
-0.88
|
-4.67
|
-2.67
|
Equity ratio,
%
|
97
|
94
|
97
|
94
|
No. of shares at the
end of the period
|
19,531,353
|
17,318,059
|
19,531,353
|
17,318,059
|
This financial statement has been produced in accordance with
IFRS for the Immunovia Group, which comprises Immunovia AB and the
wholly-owned subsidiaries, Immunovia Inc and Immunovia
GmbH.
Outlook
Immunovia is focused on fundamentally transforming diagnosis of
complex forms of cancer and autoimmune diseases. The antibody-based
platform, IMMray™, is the result of 15 years of research at CREATE
Health – the Center for Translational Cancer Research at
Lund University, Sweden. IMMray™ is a technology platform for
the development of diagnostic tests and the company's primary test,
IMMray™ PanCan–d, is the first test in the world for early
diagnosis of pancreatic cancer.
The company's financial targets remain in place from the
previous quarter. The company expects to receive the first revenues
from self-pay sales in the latter part of 2019. The following
financial targets have been established:
- Immunovia's target is to achieve turnover of SEK 250-300 million by 2022 based on self-pay for
IMMray™ PanCan–d.
- Immunovia's target is to achieve total turnover, including
payment via self-pay and cost remuneration from insurance systems,
of SEK 800-1,000 million by
2024.
About Immunovia
Immunovia AB was founded in 2007 by investigators from the
Department of Immunotechnology at Lund University and CREATE Health, the Center
for Translational Cancer Research in Lund, Sweden. Immunovia's strategy is to
decipher the wealth of information in blood and translate it into
clinically useful tools to diagnose complex diseases such as
cancer, earlier and more accurately than previously possible.
Immunovia´s core technology platform, IMMray™, is based on antibody
biomarker microarray analysis. The company is now performing
clinical validation studies for the commercialization of IMMray™
PanCan-d that could be the first blood based test for early
diagnosis of pancreatic cancer. In the beginning of 2016, the
company started a program focused on autoimmune diseases diagnosis,
prognosis and therapy monitoring. (Source: www.immunovia.com)
This information is information that Immunovia AB is obliged to
make public pursuant to the EU Market Abuse Regulation. The
information was submitted for publication, through the agency of
the contact person set out above.
Immunovia's shares (IMMNOV) are listed on Nasdaq Stockholm. For
more information, please visit www.immunovia.com.
CONTACT:
For more information, please contact:
Julie Silber
Director of Investor Relations, Immunovia
Email: julie.silber@immunovia.com
Tel: +46-7-93-486-277
This information was brought to you by Cision
http://news.cision.com
http://news.cision.com/immunovia-ab/r/immunovia-full-year-report--january-december-2018,c2741755
The following files are available for download:
https://mb.cision.com/Main/13121/2741755/991565.pdf
|
Immunovia, Q4 2018
ENG
|
View original
content:http://www.prnewswire.com/news-releases/immunovia-full-year-report-january-december-2018-300796019.html
SOURCE Immunovia AB